is currently screening for the next POWER PLAY!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Notice .02 holding with the bid whacking?
.01's - not many left - and they need to stop being greedy and sell at .02 for a 100% gain -
As these prices keep dropping - I am sure we will need some GIN - I am thinking lots of free shares were passed out on this.
The float continues going up - will be interesting to see if a promo will happen here.
DGIN CHART
I have a question - Why didn't you just sell the full 200 block?
I noticed you did in the second block of the day.
Still need to get Osama!
November 11, 2004
(CNN) -- The Arabic-language network Al-Jazeera released a full transcript Monday of the most recent videotape from Osama bin Laden in which the head of al Qaeda said his group's goal is to force America into bankruptcy.
Al-Jazeera aired portions of the videotape Friday but released the full transcript of the entire tape on its Web site Monday.
"We are continuing this policy in bleeding America to the point of bankruptcy. Allah willing, and nothing is too great for Allah," bin Laden said in the transcript.
He said the mujahedeen fighters did the same thing to the Soviet Union in Afghanistan in the 1980s, "using guerrilla warfare and the war of attrition to fight tyrannical superpowers."
"We, alongside the mujahedeen, bled Russia for 10 years until it went bankrupt and was forced to withdraw in defeat," bin Laden said.
He also said al Qaeda has found it "easy for us to provoke and bait this administration."
"All that we have to do is to send two mujahedeen to the furthest point east to raise a piece of cloth on which is written al Qaeda, in order to make generals race there to cause America to suffer human, economic and political losses without their achieving anything of note other than some benefits for their private corporations," bin Laden said.
Al-Jazeera executives said they decided to post the entire speech because rumors were circulating that the network omitted parts that "had direct threats toward specific states, which was totally untrue."
"We chose the most newsworthy parts of the address and aired them. The rest was used in lower thirds in graphics format," said one official.
U.S. intelligence officials Monday confirmed that the transcript made public Monday by Al-Jazeera was a complete one.
As part of the "bleed-until-bankruptcy plan," bin Laden cited a British estimate that it cost al Qaeda about $500,000 to carry out the attacks of September 11, 2001, an amount that he said paled in comparison with the costs incurred by the United States.
"Every dollar of al Qaeda defeated a million dollars, by the permission of Allah, besides the loss of a huge number of jobs," he said. "As for the economic deficit, it has reached record astronomical numbers estimated to total more than a trillion dollars.
The total U.S. national debt is more than $7 trillion. The U.S. federal deficit was $413 billion in 2004, according to the Treasury Department.
"It is true that this shows that al Qaeda has gained, but on the other hand it shows that the Bush administration has also gained, something that anyone who looks at the size of the contracts acquired by the shady Bush administration-linked mega-corporations, like Halliburton and its kind, will be convinced.
"And it all shows that the real loser is you," he said. "It is the American people and their economy."
As for President Bush's Iraq policy, Bin Laden said, "the darkness of black gold blurred his vision and insight, and he gave priority to private interests over the public interests of America.
"So the war went ahead, the death toll rose, the American economy bled, and Bush became embroiled in the swamps of Iraq that threaten his future," bin Laden said.
U.S. government officials said Friday that the tape appeared to be authentic and recently made. It was the first videotaped message from the al Qaeda leader in nearly three years.
http://www.cnn.com/2004/WORLD/meast/11/01/binladen.tape/
I have the cure for ya! VODKA!
Not just any ole' Vodka either - Grey Goose with Cranberry Juice - you will feel 20 years old in no time!
GO DGIN!
Happy Birthday!
USEYQ up 30% today on light volume -
On November 20, 2008, the Company and the two subsidiaries filed a motion with the Bankruptcy Court requesting an extension of the exclusive period during which the debtors have the exclusive right to solicit acceptances of the Plans from December 5, 2008 to February 27, 2009. The extension was requested to allow the debtors more time to complete negotiations with Silver Point Finance, LLC regarding a stalking horse agreement for the sale of the stock or assets of U.S. Energy Biogas Corp. and for the restructuring of the GBGH, LLC pursuant to a term sheet between the parties. The Company anticipates in the next two to four weeks (a) finalizing the stalking horse agreement and (b) incorporating the term sheet into the Plans and filing such amended Plans with the Bankruptcy Court.
Brand New Board - - nice volume today!
If your visiting - give us a boardmark!
Then read the IBOX - especially the bolded parts.
IVVI - news and chart - 10 million O/S - only 3.6 million float - NASDAQ stock - 65% insider holding - with volume - this rocks hard!
Share Structure: http://www.shortsqueeze.com/?symbol=ivvi
Cleveland Clinic to Present Results from Study Using Ivivi Technologies' tPEMF(tm) on Cardiac Ischemia At American College of Cardiology Annual Meeting
8:01a ET January 15, 2009 (GlobeNewswire)
Ivivi Technologies, Inc. (Nasdaq:IVVI), a leader in non-invasive, electrotherapy systems, today announced that previously announced results from a double-blind, randomized, placebo-controlled and prospective clinical trial on "no-option" cardiac patients utilizing the Company's proprietary targeted pulsed electromagnetic field (tPEMF(tm)) technology have been peer reviewed and accepted for presentation at the American College of Cardiology (ACC) 58th Annual Scientific Meeting, March 29-31, 2009 in Orlando, Florida.
The paper, titled "Use of Pulsed Electromagnetic Fields For Ischemic Cardiomyopathy Therapy (EFFECT Trial): A Randomized, Double-Blind, Parallel, Placebo-Controlled, Prospective Trial" will be presented by Dr. Michael Shen, a cardiologist at the Cleveland Clinic in Westin, Florida and Principal Investigator of the EFFECT trial.
As announced by Ivivi on June 30, 2008, in a study of 30 patients with cardiomyopathies and no other treatment options, patients in the active treatment arm demonstrated significant reductions in anginal pain and improvements in physical activity. These results began emerging at one month after commencement of treatment, with increasing significance at three and five month intervals. The changes in clinical outcomes were consistent with those seen in angina patients for whom a standard therapeutic intervention is possible.
The peer-reviewed abstract concludes: "This is the first study using PEMF in patients with angina and ischemic heart disease (IHD). This pilot trial demonstrates that PEMF is safe to use and effective in achieving and sustaining improvements in angina severity and physical capacity in patients with IHD and failed standard medical therapy and revascularization options. This device has the unique advantages of being non-invasive, non-pharmacological and self-operated at home. Future studies are warranted to investigate mechanistic effects, perfusion changes and clinical outcomes in a large clinical trial."
Dr. Shen added, "In my experience PEMF clearly has significant potential to change clinical cardiology and could provide new hope to patients with angina and ischemic cardiomyopathy."
Steven Gluckstern, Chairman of Ivivi Technologies, stated, "The ACC Meeting is one of the most important in the field of cardiology and we are pleased that research on our tPEMF(tm) technology was recognized for presentation. We believe this gives Ivivi credibility as we continue to evaluate our tPEMF(tm) technology in the field of cardiology with the intention to design and implement a larger, multi-center human clinical trial to confirm the important clinical outcomes and the perfusion benefits seen."
About the EFFECT Trial
The objectives of this trial with tPEMF(tm) technology in this patient population were to evaluate safety; measure tPEMF(tm) effects on myocardial perfusion, ventricular function, clinical symptoms of angina, physical limitations; and the sustainability of any effects 2 months after treatment was completed. The patients administered treatment to themselves at home for 30 minutes, twice a day for 3 months. This consisted of placing a lightweight vest over the chest, which held a circular applicator over the left breast. Patients were evaluated at baseline, 1, 3 and 5 month intervals, with patients receiving the active treatment showing significant reductions in anginal pain and frequency. As the improvements at the 5 month point demonstrated the highest significance, these improvements persisted even after the therapy had been stopped for 2 months. There were dramatic increases in cardiac perfusion for some, but not most, patients at the 5 month period, which was expected because of the short study duration. Patients are currently being recalled to determine their present perfusion status. FDA approval for this indication is necessary in order for Ivivi to commercialize its product.
About Ivivi Technologies, Inc.
Based in Montvale, NJ, Ivivi Technologies, Inc. is a medical technology company focusing on designing, developing and commercializing its proprietary electrotherapeutic technology platform, with a primary focus on developing treatments for cardiovascular disease. Ivivi's research and development activities are focused specifically on targeted pulsed electromagnetic field, or tPEMF(tm), technology, which, by creating a therapeutic electrical current in injured soft tissue, is believed to modulate biochemical and physiological healing processes to help reduce related pain and inflammation. The Company's most recent clinical studies have shown reductions in anginal pain and increases in blood flow to the heart in certain cardiac patients; however, additional studies are required in this area. The Company expects to develop new tPEMF(tm) devices and to seek strategic partners to pursue the cardiac market and others, such as osteoarthritis, neurology and other inflammatory-related conditions if FDA marketing approvals or clearances can be achieved in these areas. Dr. Michael Shen, cardiologist at the Cleveland Clinic and Principal Investigator of the EFFECT trial, is a paid consultant to Ivivi Technologies in regard to his research on Ivivi's tPEMF(tm).
Forward-Looking Statements
This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those related to additional clinical trials, strategic partnerships and future sales. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the Company's limited operating history, history of significant and continued operating losses and substantial accumulated earnings deficit, difficulties with its financial accounting controls, the failure of the market for the Company's products to continue to develop, the inability for customers to receive third party reimbursement, the inability to obtain additional capital, the inability to protect the Company's intellectual property, the loss of any executive officers or key personnel or consultants, competition, changes in the regulatory landscape or the imposition of regulations that affect the Company's products and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission, including the Company's Form 10-KSB for the fiscal year ended March 31, 2008. The Company assumes no obligation to update the information contained in this press release.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Ivivi Technologies, Inc.
Share Structure:
Ivivi Technologies Inc. $ 0.28
IVVI 0.00
Short Interest (Shares Short) 5,600
Days To Cover (Short Interest Ratio) 0.1
Short Percent of Float 0.15 %
Short Interest - Prior 29,500
Short % Increase / Decrease -81.02 %
Short Squeeze Ranking™
% From 52-Wk High ($ 1.07 ) -282.14 %
% From 52-Wk Low ($ 0.11 ) 60.71 %
% From 200-Day MA ($ 0.29 ) -3.57 %
% From 50-Day MA ($ 0.27 ) 3.57 %
Price % Change (52-Week) %
Shares Float 3,680,000
Total Shares Outstanding 10,116,930
% Owned by Insiders 63.06 %
% Owned by Institutions 11.80 %
Market Cap. $ 2,832,740
Trading Volume - Today 2,978
Trading Volume - Average 73,300
Trading Volume - Today vs. Average 4.06 %
Earnings Per Share -0.82
PE Ratio
Record Date 2009-JanA
Sector Healthcare
Industry Medical Appliances & Equipment
Exchange NAS
Significant Levels On The Dow
December 6, 1974 577 The last Bear Market bottom
July 12, 1976 1011 Highest point between Jan '73 and Oct. '82
August 12, 1982 776 The start of the "Reagan Bull"
August 25, 1987 2722 The 1987 high
October 19, 1987 1738 The (508 point) crash of 1987
February 2, 1994 3975 The top of the post 1987 crash recovery
November 23, 1994 3674 The start of the Clinton "super bull"
March 29, 1999 10006 The first Dow close above 10000
January 14, 2000 11723 The "Clinton bull" high
March 17, 2000 10630 The biggest one day gain (499 points)
March 20, 2001 9720 Dow closes below previous year low -
first time since 1982
Sept 11-14, 2001 9605 Terrorist attack - Dow closed for four days
Sept 17, 2000 8920 The biggest one day fall (685 points)
Sept. 21, 2001 8235 Dow's second worst week ever -14.26%
Dec 31, 2001 10021 Dow up 21.7% from Sept. 21 low but down 7.2% on the year
July 23, 2002 7702 Low close of break below post 9/11 low.
Sept 30, 2002 7591 New 2002 low - All treasury yields (except
30-year bond) at 2002 lows.
Oct 9, 2002 7286 New 2002 low - Dow down 37.8% from Jan 14, 2000 all time high.
Oct 31, 2002 8397 Dow up 806 points (10.6%) for Oct. First "up" month since March.
Nov 6, 2002 8771 Fed cuts rates for first time since Dec. 2001 - 0.50% - Fed Funds 1.25% - Discount 0.75%
Dec 31, 2002 8341 Dow down 16.8% for 2002. First three consecutive year loss since 1939-41
May 23, 2003 8601 Senate passes bill raising the Treasury debt limit by $US 984 Billion to $US 7.384 TRILLION
June 25, 2003 9011 Fed cuts rates by 0.25% to a post 1958 low of 1.00%
Dec 31, 2003 10453 Dow up 25.32% in 2003 - Dollar down 14.67% in 2003
October 3, 2006 11727 Dow exceeds its January 14, 2000 high of 11723
October 9, 2007 14164 New all time high on the Dow
July 2, 2008 11215 Dow closes more than 20% below its Oct.
2007 high - bear market
Oct 9, 2002 7286 New 2002 low - Dow down 37.8% from Jan 14, 2000 all time high.
November 23, 1994 Dow Jones Industrial Average 3674 The start of the Clinton "super bull"
Oct 9, 2002 7286 New 2002 low - Dow down 37.8% from Jan 14, 2000 all time high.
IVVI - news and chart - 10 million O/S - only 3.6 million float - NASDAQ stock - 65% insider holding - with volume - this rocks hard!
Cleveland Clinic to Present Results from Study Using Ivivi Technologies' tPEMF(tm) on Cardiac Ischemia At American College of Cardiology Annual Meeting
8:01a ET January 15, 2009 (GlobeNewswire)
Ivivi Technologies, Inc. (Nasdaq:IVVI), a leader in non-invasive, electrotherapy systems, today announced that previously announced results from a double-blind, randomized, placebo-controlled and prospective clinical trial on "no-option" cardiac patients utilizing the Company's proprietary targeted pulsed electromagnetic field (tPEMF(tm)) technology have been peer reviewed and accepted for presentation at the American College of Cardiology (ACC) 58th Annual Scientific Meeting, March 29-31, 2009 in Orlando, Florida.
The paper, titled "Use of Pulsed Electromagnetic Fields For Ischemic Cardiomyopathy Therapy (EFFECT Trial): A Randomized, Double-Blind, Parallel, Placebo-Controlled, Prospective Trial" will be presented by Dr. Michael Shen, a cardiologist at the Cleveland Clinic in Westin, Florida and Principal Investigator of the EFFECT trial.
As announced by Ivivi on June 30, 2008, in a study of 30 patients with cardiomyopathies and no other treatment options, patients in the active treatment arm demonstrated significant reductions in anginal pain and improvements in physical activity. These results began emerging at one month after commencement of treatment, with increasing significance at three and five month intervals. The changes in clinical outcomes were consistent with those seen in angina patients for whom a standard therapeutic intervention is possible.
The peer-reviewed abstract concludes: "This is the first study using PEMF in patients with angina and ischemic heart disease (IHD). This pilot trial demonstrates that PEMF is safe to use and effective in achieving and sustaining improvements in angina severity and physical capacity in patients with IHD and failed standard medical therapy and revascularization options. This device has the unique advantages of being non-invasive, non-pharmacological and self-operated at home. Future studies are warranted to investigate mechanistic effects, perfusion changes and clinical outcomes in a large clinical trial."
Dr. Shen added, "In my experience PEMF clearly has significant potential to change clinical cardiology and could provide new hope to patients with angina and ischemic cardiomyopathy."
Steven Gluckstern, Chairman of Ivivi Technologies, stated, "The ACC Meeting is one of the most important in the field of cardiology and we are pleased that research on our tPEMF(tm) technology was recognized for presentation. We believe this gives Ivivi credibility as we continue to evaluate our tPEMF(tm) technology in the field of cardiology with the intention to design and implement a larger, multi-center human clinical trial to confirm the important clinical outcomes and the perfusion benefits seen."
About the EFFECT Trial
The objectives of this trial with tPEMF(tm) technology in this patient population were to evaluate safety; measure tPEMF(tm) effects on myocardial perfusion, ventricular function, clinical symptoms of angina, physical limitations; and the sustainability of any effects 2 months after treatment was completed. The patients administered treatment to themselves at home for 30 minutes, twice a day for 3 months. This consisted of placing a lightweight vest over the chest, which held a circular applicator over the left breast. Patients were evaluated at baseline, 1, 3 and 5 month intervals, with patients receiving the active treatment showing significant reductions in anginal pain and frequency. As the improvements at the 5 month point demonstrated the highest significance, these improvements persisted even after the therapy had been stopped for 2 months. There were dramatic increases in cardiac perfusion for some, but not most, patients at the 5 month period, which was expected because of the short study duration. Patients are currently being recalled to determine their present perfusion status. FDA approval for this indication is necessary in order for Ivivi to commercialize its product.
About Ivivi Technologies, Inc.
Based in Montvale, NJ, Ivivi Technologies, Inc. is a medical technology company focusing on designing, developing and commercializing its proprietary electrotherapeutic technology platform, with a primary focus on developing treatments for cardiovascular disease. Ivivi's research and development activities are focused specifically on targeted pulsed electromagnetic field, or tPEMF(tm), technology, which, by creating a therapeutic electrical current in injured soft tissue, is believed to modulate biochemical and physiological healing processes to help reduce related pain and inflammation. The Company's most recent clinical studies have shown reductions in anginal pain and increases in blood flow to the heart in certain cardiac patients; however, additional studies are required in this area. The Company expects to develop new tPEMF(tm) devices and to seek strategic partners to pursue the cardiac market and others, such as osteoarthritis, neurology and other inflammatory-related conditions if FDA marketing approvals or clearances can be achieved in these areas. Dr. Michael Shen, cardiologist at the Cleveland Clinic and Principal Investigator of the EFFECT trial, is a paid consultant to Ivivi Technologies in regard to his research on Ivivi's tPEMF(tm).
Forward-Looking Statements
This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those related to additional clinical trials, strategic partnerships and future sales. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the Company's limited operating history, history of significant and continued operating losses and substantial accumulated earnings deficit, difficulties with its financial accounting controls, the failure of the market for the Company's products to continue to develop, the inability for customers to receive third party reimbursement, the inability to obtain additional capital, the inability to protect the Company's intellectual property, the loss of any executive officers or key personnel or consultants, competition, changes in the regulatory landscape or the imposition of regulations that affect the Company's products and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission, including the Company's Form 10-KSB for the fiscal year ended March 31, 2008. The Company assumes no obligation to update the information contained in this press release.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Ivivi Technologies, Inc.
7449 is 52 week low and that must hold - if it falls below that - technically - the next bottom rivals that of 2002 and 1998 levels - if those fail - WOW is all I have to say!
Another DOW CHART! 7449 is 52 week low!
IVVI - Share structure: SHARES FLOAT 3,680,000 -
63% insider holding!
Ivivi Technologies Inc. $ 0.28
IVVI 0.00
Short Interest (Shares Short) 5,600
Days To Cover (Short Interest Ratio) 0.1
Short Percent of Float 0.15 %
Short Interest - Prior 29,500
Short % Increase / Decrease -81.02 %
Short Squeeze Ranking™
% From 52-Wk High ($ 1.07 ) -282.14 %
% From 52-Wk Low ($ 0.11 ) 60.71 %
% From 200-Day MA ($ 0.29 ) -3.57 %
% From 50-Day MA ($ 0.27 ) 3.57 %
Price % Change (52-Week) %
Shares Float 3,680,000
Total Shares Outstanding 10,116,930
% Owned by Insiders 63.06 %
% Owned by Institutions 11.80 %
Market Cap. $ 2,832,740
Trading Volume - Today 2,978
Trading Volume - Average 73,300
Trading Volume - Today vs. Average 4.06 %
Earnings Per Share -0.82
PE Ratio
Record Date 2009-JanA
IVVI chart & news:
Cleveland Clinic to Present Results from Study Using Ivivi Technologies' tPEMF(tm) on Cardiac Ischemia At American College of Cardiology Annual Meeting
8:01a ET January 15, 2009 (GlobeNewswire)
Ivivi Technologies, Inc. (Nasdaq:IVVI), a leader in non-invasive, electrotherapy systems, today announced that previously announced results from a double-blind, randomized, placebo-controlled and prospective clinical trial on "no-option" cardiac patients utilizing the Company's proprietary targeted pulsed electromagnetic field (tPEMF(tm)) technology have been peer reviewed and accepted for presentation at the American College of Cardiology (ACC) 58th Annual Scientific Meeting, March 29-31, 2009 in Orlando, Florida.
The paper, titled "Use of Pulsed Electromagnetic Fields For Ischemic Cardiomyopathy Therapy (EFFECT Trial): A Randomized, Double-Blind, Parallel, Placebo-Controlled, Prospective Trial" will be presented by Dr. Michael Shen, a cardiologist at the Cleveland Clinic in Westin, Florida and Principal Investigator of the EFFECT trial.
As announced by Ivivi on June 30, 2008, in a study of 30 patients with cardiomyopathies and no other treatment options, patients in the active treatment arm demonstrated significant reductions in anginal pain and improvements in physical activity. These results began emerging at one month after commencement of treatment, with increasing significance at three and five month intervals. The changes in clinical outcomes were consistent with those seen in angina patients for whom a standard therapeutic intervention is possible.
The peer-reviewed abstract concludes: "This is the first study using PEMF in patients with angina and ischemic heart disease (IHD). This pilot trial demonstrates that PEMF is safe to use and effective in achieving and sustaining improvements in angina severity and physical capacity in patients with IHD and failed standard medical therapy and revascularization options. This device has the unique advantages of being non-invasive, non-pharmacological and self-operated at home. Future studies are warranted to investigate mechanistic effects, perfusion changes and clinical outcomes in a large clinical trial."
Dr. Shen added, "In my experience PEMF clearly has significant potential to change clinical cardiology and could provide new hope to patients with angina and ischemic cardiomyopathy."
Steven Gluckstern, Chairman of Ivivi Technologies, stated, "The ACC Meeting is one of the most important in the field of cardiology and we are pleased that research on our tPEMF(tm) technology was recognized for presentation. We believe this gives Ivivi credibility as we continue to evaluate our tPEMF(tm) technology in the field of cardiology with the intention to design and implement a larger, multi-center human clinical trial to confirm the important clinical outcomes and the perfusion benefits seen."
About the EFFECT Trial
The objectives of this trial with tPEMF(tm) technology in this patient population were to evaluate safety; measure tPEMF(tm) effects on myocardial perfusion, ventricular function, clinical symptoms of angina, physical limitations; and the sustainability of any effects 2 months after treatment was completed. The patients administered treatment to themselves at home for 30 minutes, twice a day for 3 months. This consisted of placing a lightweight vest over the chest, which held a circular applicator over the left breast. Patients were evaluated at baseline, 1, 3 and 5 month intervals, with patients receiving the active treatment showing significant reductions in anginal pain and frequency. As the improvements at the 5 month point demonstrated the highest significance, these improvements persisted even after the therapy had been stopped for 2 months. There were dramatic increases in cardiac perfusion for some, but not most, patients at the 5 month period, which was expected because of the short study duration. Patients are currently being recalled to determine their present perfusion status. FDA approval for this indication is necessary in order for Ivivi to commercialize its product.
About Ivivi Technologies, Inc.
Based in Montvale, NJ, Ivivi Technologies, Inc. is a medical technology company focusing on designing, developing and commercializing its proprietary electrotherapeutic technology platform, with a primary focus on developing treatments for cardiovascular disease. Ivivi's research and development activities are focused specifically on targeted pulsed electromagnetic field, or tPEMF(tm), technology, which, by creating a therapeutic electrical current in injured soft tissue, is believed to modulate biochemical and physiological healing processes to help reduce related pain and inflammation. The Company's most recent clinical studies have shown reductions in anginal pain and increases in blood flow to the heart in certain cardiac patients; however, additional studies are required in this area. The Company expects to develop new tPEMF(tm) devices and to seek strategic partners to pursue the cardiac market and others, such as osteoarthritis, neurology and other inflammatory-related conditions if FDA marketing approvals or clearances can be achieved in these areas. Dr. Michael Shen, cardiologist at the Cleveland Clinic and Principal Investigator of the EFFECT trial, is a paid consultant to Ivivi Technologies in regard to his research on Ivivi's tPEMF(tm).
Forward-Looking Statements
This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those related to additional clinical trials, strategic partnerships and future sales. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the Company's limited operating history, history of significant and continued operating losses and substantial accumulated earnings deficit, difficulties with its financial accounting controls, the failure of the market for the Company's products to continue to develop, the inability for customers to receive third party reimbursement, the inability to obtain additional capital, the inability to protect the Company's intellectual property, the loss of any executive officers or key personnel or consultants, competition, changes in the regulatory landscape or the imposition of regulations that affect the Company's products and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission, including the Company's Form 10-KSB for the fiscal year ended March 31, 2008. The Company assumes no obligation to update the information contained in this press release.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Ivivi Technologies, Inc.
Not looking good bro!
Think landfill gas isn't the fer shizzle? LOL
http://www.epa.gov/lmop/
UK Energy Systems Limited
UK Energy Systems, Limited (UKES) is a UK-based energy company specializing in natural gas exploration, production and transportation as well as related power generation. The UK is the world’s third largest consumer of natural gas. UKES is the newest and largest subsidiary of U.S. Energy Systems, formed in August 2006 with the completion of a series of acquisitions.
Headquartered in Knapton, UKES owns and operates Viking UK Gas Ltd., founded in 1979. The company currently owns the licenses to six proved gas fields (four developed and producing, and two undeveloped). All existing reserves are located in the North Yorkshire region of the UK. In addition, UKES owns all the associated collection, transportation and processing facilities for the proved fields, as well as a 42 MW single cycle, LM 6000 gas turbine powered by the fields' produced gas. UKES has an existing commercial agreement with ScottishPower via long-term power purchase and gas sales agreements.
UKES's objectives for the North Yorkshire project are to maximize the efficiency and power production of the gas turbine, maximize natural gas production from its producing and undeveloped gas fields, and ultimately to sell natural gas into the UK wholesale market. UKES has clear strategies for achieving each of these objectives.
Led by an experienced, world class management team, UKES is also examining a variety
of long-term and strategic growth opportunities, including:
Further natural gas exploration and production from regional on-shore unexplored reserves.
Potential tolling arrangements.
Vertically integrating the company into the natural gas value chain.
USEYQ starting with much better volume today!
Things are going fantastic!
Just have to figure out what looks good in a trashed market!
Its just a matter of time here - I will be buying today.
With some volume she blows!
These are all OTC stock bro. This board is playing the still listed companies!
The one thing really lacking is good news! Not going to have any - so what can drive the DOW back up?
You did respond.
Stevenvegas is my roomate - just because he posts here regularly? You are a little off.
No problem! If you have any other questions - don't hesitate to ask.
500,000,000
New share structure has been added to the IBOX - I have been informed that increases will still continue - I will be updating the IBOX accordingly on a weekly basis - until O/S growth slows down.
Your laughter and happiness at the expense of another members huge loss - wouldn't that reverse the KARMA in the your direction?
Also added quick links to company websites.
This was formerly in the IBOX. I still think a link to the reverse split should be available.
Oh yeah - I forgot - this one isn't about the money - LOL!
You are correct - except 1 thing - the company votes to give themselves hundreds of millions of more shares and begin diluting immediately - and the PPS will never sell after R/S for the PPS before - because people know it is a falling knife - they put crazy low bids in - and start getting filled!
DGIN for example - should of been $2.50 per share and ask is at .30 - a share was never sold for $2.50
his is interesting:
As previously reported on January 16, 2008, U.S. Energy Systems, Inc. (the "Company") and two of its subsidiaries, U.S. Energy Overseas Investments LLC and GBGH, LLC, filed voluntary petitions to commence cases under chapter 11 of Title 11 of the United States Code on January 9, 2008 in the United States Bankruptcy Court for the Southern District of New York (the "Bankruptcy Court"). On August 22, 2008, the Company and the two subsidiaries filed Plans of Reorganization (the "Plans") with the Bankruptcy Court. The Plans remain subject to modification and revision.
On November 20, 2008, the Company and the two subsidiaries filed a motion with the Bankruptcy Court requesting an extension of the exclusive period during which the debtors have the exclusive right to solicit acceptances of the Plans from December 5, 2008 to February 27, 2009. The extension was requested to allow the debtors more time to complete negotiations with Silver Point Finance, LLC regarding a stalking horse agreement for the sale of the stock or assets of U.S. Energy Biogas Corp. and for the restructuring of the GBGH, LLC pursuant to a term sheet between the parties. The Company anticipates in the next two to four weeks (a) finalizing the stalking horse agreement and (b) incorporating the term sheet into the Plans and filing such amended Plans with the Bankruptcy Court.
http://biz.yahoo.com/e/081125/useyq.pk8-k.html
Chart:
Very small volume today - but nearing 52 week low with an exciting future. Great opp's IMO!
Didn't realize this board was already created.
Held up well considering the markets today!